180 related articles for article (PubMed ID: 18380646)
1. Adoption of pharmaceutical innovation and the growth of drug expenditure in Taiwan: is it cost effective?
Hsieh CR; Sloan FA
Value Health; 2008; 11(2):334-44. PubMed ID: 18380646
[TBL] [Abstract][Full Text] [Related]
2. The adoption of pharmaceutical innovation and its impact on the treatment costs for Alzheimer's disease in Taiwan.
Lo TF; Hsieh CR
J Ment Health Policy Econ; 2014 Sep; 17(3):107-17. PubMed ID: 25543114
[TBL] [Abstract][Full Text] [Related]
3. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly.
Liu SZ; Romeis JC
Med Care; 2003 Dec; 41(12):1331-42. PubMed ID: 14668666
[TBL] [Abstract][Full Text] [Related]
4. The evolution of Taiwan's National Health Insurance drug reimbursement scheme.
Hsu JC; Lu CY
Daru; 2015 Feb; 23(1):15. PubMed ID: 25889754
[TBL] [Abstract][Full Text] [Related]
5. Propaganda or the cost of innovation? Challenging the high price of new drugs.
Ghinea N; Lipworth W; Kerridge I
BMJ; 2016 Mar; 352():i1284. PubMed ID: 26968991
[No Abstract] [Full Text] [Related]
6. Rational prescribing in primary care (RaPP): economic evaluation of an intervention to improve professional practice.
Fretheim A; Aaserud M; Oxman AD
PLoS Med; 2006 Jun; 3(6):e216. PubMed ID: 16737349
[TBL] [Abstract][Full Text] [Related]
7. New drugs and the growth of health expenditure: evidence from diabetic patients in Taiwan.
Liu YM; Hsieh CR
Health Econ; 2012 May; 21(5):496-513. PubMed ID: 21394819
[TBL] [Abstract][Full Text] [Related]
8. The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugs.
Chen CL; Chen L; Yang WC
BMC Public Health; 2008 Apr; 8():118. PubMed ID: 18405385
[TBL] [Abstract][Full Text] [Related]
9. [Assessment of the pharmaceutical expenditure in Hungary].
Inotai A; Merész G; Kaló Z
Acta Pharm Hung; 2010; 80(4):162-72. PubMed ID: 21404477
[TBL] [Abstract][Full Text] [Related]
10. The economic aspects of drug use.
Haaijer-Ruskamp FM; Dukes MN
WHO Reg Publ Eur Ser; 1993; 45():125-45. PubMed ID: 8442842
[No Abstract] [Full Text] [Related]
11. Spending on medicines in Israel in an international context.
Sax P
Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
[TBL] [Abstract][Full Text] [Related]
12. The impact of reference-pricing systems in Europe: a literature review and case studies.
Dylst P; Vulto A; Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):729-37. PubMed ID: 22098289
[TBL] [Abstract][Full Text] [Related]
13. The impotence of price controls: failed attempts to constrain pharmaceutical expenditures in Greece.
Lambrelli D; O'Donnell O
Health Policy; 2011 Jul; 101(2):162-71. PubMed ID: 20884073
[TBL] [Abstract][Full Text] [Related]
14. Impact of separating drug prescribing and dispensing on provider behaviour: Taiwan's experience.
Chou YJ; Yip WC; Lee CH; Huang N; Sun YP; Chang HJ
Health Policy Plan; 2003 Sep; 18(3):316-29. PubMed ID: 12917273
[TBL] [Abstract][Full Text] [Related]
15. The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999-2010.
Lichtenberg FR; Tatar M; Çalışkan Z
Health Policy; 2014 Sep; 117(3):361-73. PubMed ID: 24996837
[TBL] [Abstract][Full Text] [Related]
16. Estimated annual direct expenditures in the United States as a result of inappropriate hypertension treatment according to national treatment guidelines.
Balu S
Clin Ther; 2009 Jul; 31(7):1581-94. PubMed ID: 19695408
[TBL] [Abstract][Full Text] [Related]
17. The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000-2009.
Lichtenberg FR
Econ Hum Biol; 2014 Mar; 13():107-27. PubMed ID: 23664114
[TBL] [Abstract][Full Text] [Related]
18. Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003.
Lee YC; Yang MC; Huang YT; Liu CH; Chen SB
Pharmacoeconomics; 2006; 24(9):891-902. PubMed ID: 16942123
[TBL] [Abstract][Full Text] [Related]
19. The power of r - pharmaceutical sales decomposition in Cyprus public healthcare sector and determinants of drug expenditure evolution: any lessons learned?
Petrou P
Expert Rev Pharmacoecon Outcomes Res; 2014 Apr; 14(2):289-300. PubMed ID: 24580120
[TBL] [Abstract][Full Text] [Related]
20. The determinants of the adoption of pharmaceutical innovation: evidence from Taiwan.
Liu YM; Yang YH; Hsieh CR
Soc Sci Med; 2011 Mar; 72(6):919-27. PubMed ID: 21333432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
